ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04526197
- Locations
- 🇺🇸
Clinical Trial Site, Austin, Texas, United States
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
Phase 3
Active, not recruiting
- Conditions
- AL Amyloidosis
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT04512235
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Phase 3
Active, not recruiting
- Conditions
- AL Amyloidosis
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04504825
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
Phase 3
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT04469465
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of Danicopan in Participants of Japanese Descent
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04451434
- Locations
- 🇦🇺
Clinical Study Site, Brisbane, Australia
Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04422431
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
Phase 3
Terminated
- Conditions
- Acute Lung InjuryPneumonia, ViralCOVID-19 Severe PneumoniaAcute Respiratory Distress Syndrome
- Interventions
- Biological: RavulizumabOther: BSC
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT04369469
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19
- Conditions
- COVID-19Pneumonia, ViralAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT04355494
- Locations
- 🇺🇸
Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇫🇷Hôpital Henri Mondor, Creteil, France
Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
Phase 4
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04320602
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
🇬🇧Research Site, London, United Kingdom
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04304144
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath